Evogene to Present at H.C. Wainwright 27th Annual Global Investment Conference in New York
Evogene (NASDAQ: EVGN) announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference in New York from September 8-10, 2025. CEO Ofer Haviv will present on September 10, 2025, at 1:00 PM ET, focusing on the company's strategic shift towards maximizing value from its ChemPass AI technology for small molecule discovery in pharmaceutical and agricultural applications.
The presentation will showcase the company's proprietary generative AI tech-engine capabilities. One-on-one meetings with management will be available for interested investors and companies attending the conference.
Evogene (NASDAQ: EVGN) ha comunicato la sua partecipazione al H.C. Wainwright 27th Annual Global Investment Conference a New York, dall'8 al 10 settembre 2025. Il CEO Ofer Haviv terrà una presentazione il 10 settembre 2025 alle 13:00 ET, concentrandosi sul cambiamento strategico dell'azienda volto a massimizzare il valore della sua tecnologia ChemPass AI per la scoperta di piccole molecole in ambito farmaceutico e agricolo.
La presentazione illustrerà le capacità proprietarie di generative AI tech-engine dell'azienda. Sono previste sessioni individuali con il management per investitori e società interessate presenti alla conferenza.
Evogene (NASDAQ: EVGN) anunció su participación en la H.C. Wainwright 27th Annual Global Investment Conference en Nueva York, del 8 al 10 de septiembre de 2025. El CEO Ofer Haviv presentará el 10 de septiembre de 2025 a la 1:00 PM ET, centrando la exposición en el cambio estratégico de la compañía para maximizar el valor de su tecnología ChemPass AI en el descubrimiento de pequeñas moléculas para aplicaciones farmacéuticas y agrícolas.
La presentación mostrará las capacidades propietarias del motor tecnológico de IA generativa de la compañía. Habrá reuniones individuales con la dirección disponibles para inversores y empresas asistentes a la conferencia.
Evogene (NASDAQ: EVGN)는 2025년 9월 8일부터 10일까지 뉴욕에서 열리는 H.C. Wainwright 제27회 연례 글로벌 투자 콘퍼런스에 참가한다고 발표했습니다. CEO 오퍼 하비브(Ofer Haviv)는 2025년 9월 10일 오후 1시(ET)에 발표를 진행하며, 제약 및 농업 분야의 소분자 탐색을 위한 자사의 ChemPass AI 기술로부터 가치를 극대화하기 위한 전략적 전환에 초점을 맞출 예정입니다.
발표에서는 회사의 독점적인 생성형 AI 기술 엔진 역량을 선보일 예정입니다. 컨퍼런스 참석 투자자 및 기업을 대상으로 경영진과의 일대일 미팅도 제공됩니다.
Evogene (NASDAQ: EVGN) a annoncé sa participation à la H.C. Wainwright 27th Annual Global Investment Conference à New York, du 8 au 10 septembre 2025. Le CEO Ofer Haviv présentera le 10 septembre 2025 à 13h00 ET, en mettant l'accent sur l'orientation stratégique de la société visant à maximiser la valeur de sa technologie ChemPass AI pour la découverte de petites molécules dans les domaines pharmaceutique et agricole.
La présentation mettra en avant les capacités propriétaires du moteur technologique d'IA générative de l'entreprise. Des rendez-vous individuels avec la direction seront proposés aux investisseurs et sociétés présents à la conférence.
Evogene (NASDAQ: EVGN) gab seine Teilnahme an der H.C. Wainwright 27th Annual Global Investment Conference in New York vom 8. bis 10. September 2025 bekannt. CEO Ofer Haviv wird am 10. September 2025 um 13:00 Uhr ET präsentieren und den strategischen Wandel des Unternehmens hervorheben, der darauf abzielt, den Wert der ChemPass AI-Technologie für die Entdeckung kleiner Moleküle in pharmazeutischen und landwirtschaftlichen Anwendungen zu maximieren.
Die Präsentation zeigt die firmeneigenen Fähigkeiten der generativen AI-Tech-Engine. Für interessierte Investoren und Unternehmen auf der Konferenz werden Einzelgespräche mit dem Management angeboten.
- None.
- None.
REHOVOT,
Mr. Haviv's in-person presentation will highlight Evogene's new strategic focus on maximizing the value of ChemPass AI, the company's proprietary generative AI tech-engine, for the discovery and optimization of small molecules in both the pharmaceutical and agriculture industries. The presentation is scheduled for Wednesday, September 10, 2025, at 1:00 PM ET.
Mr. Haviv will also be available for one-on-one meetings. Interested investors and companies attending the conference are welcome to contact Evogene's Investor Relations team (details below) or, for H.C. Wainwright clients, schedule meetings directly through the conference's online platform.
About Evogene Ltd.
Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN) is a pioneering AI-driven discovery and development company focused on creating novel small molecules for the pharmaceutical and ag-chemical industries. At the heart of Evogene's innovation is ChemPass AI, a proprietary generative AI tech-engine purpose-built to design highly potent and unique small molecules optimized across multiple critical parameters. By leveraging its tech-engine, Evogene address key challenges in small molecule discovery and optimization – significantly increasing the probability of success while reducing time and development costs. Evogene's powerful tech-engine drives product innovation through both strategic partnerships and collaborations, as well as through its internal proprietary product pipelines.
For more information, please visit: www.evogene.com.
Contact:
ir@evogene.com
Tel: +972-8-9311901
Logo: https://mma.prnewswire.com/media/1947468/Evogene_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/evogene-to-present-at-hc-wainwright-27th-annual-global-investment-conference-in-new-york-302540962.html
SOURCE Evogene
FAQ
When is Evogene (EVGN) presenting at the H.C. Wainwright Conference 2025?
What will Evogene (EVGN) discuss at the H.C. Wainwright Conference?
How can investors meet with Evogene management at the H.C. Wainwright Conference?
What is Evogene's ChemPass AI technology?
